Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL
OncLive,
Matthew S. Davids, MD, MMSc Treatment with acalabrutinib (Calquence)–based regimens led to long-term efficacy in patients with…
Matthew S. Davids, MD, MMSc Treatment with acalabrutinib (Calquence)–based regimens led to long-term efficacy in patients with…
Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed…
In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in…